李育誠(Lee, Yu-Cheng) 助理教授

Email
yclee0212@tmu.edu.tw
現   職
醫學科學研究所 助理教授

學經歷

學 歷

畢業學校與學位[修業時間]
國立成功大學基礎醫學研究所 博士
2007/09~2013/07
國立中山大學生物醫學研究所 碩士
2004/09~2006/06
高雄醫學大學醫學技術學系 學士
2000/09~2004/06

本校學術經歷

任職單位與職稱[起迄時間]
醫學科學研究所助理教授
2019/08/26~

本校兼職教學行政經歷

服務單位與職稱[起迄時間]
無資料!

其它經歷

任職單位與職稱[起迄時間]
貝勒醫學院分子及細胞生物學研究所博士後研究員
2015/03/16~2019/08/14

專長與研究領域

學門領域
生化及藥理醫學
Biochemistry and Pharmacology
腫瘤
Oncology
學術專長
抗癌藥物
抗癌藥物
細胞訊息傳遞
細胞訊息傳遞
細胞週期
細胞週期
癌症細胞生物學
癌症細胞生物學
腫瘤轉移
腫瘤轉移
膀胱癌
膀胱癌

論文著作

清冊下載


1. 2022 Yu-Cheng Lee,Cheng-Han Lin, Wei-Lun Chang, Wen-Der Lin,Jhih-Kai Pan ,Wei-Jan Wang, Bor-Chyuan Su, Hsien-Hui Chung, Chen-Hsun Tsai, Forn-Chia Lin , Wen-Ching Wang , Pei-Jung Lu . Concurrent Chemoradiotherapy-Driven Cell Plasticity by miR-200 Family Implicates the Therapeutic Response of Esophageal Squamous Cell Carcinoma . International Journal of Molecular Sciences .2022

2. 2022 Yu-Cheng Lee,Hung-Ming Lam,Charles Rosser,Dan Theodorescu,William C Parks ,Keith Syson Chan . The dynamic roles of the bladder tumour microenvironment . Nature Reviews Urology .2022

3. 2022 Sungyong You,Minhyung Kim,Xen Ping Hoi ,Yu Cheng Lee , Li Wang,David Spetzler, Jim Abraham, Dan Magee, Prerna Jain, Matthew D Galsky, Keith Syson Chan, Dan Theodorescu. Discoidin Domain Receptor-Driven Gene Signatures as Markers of Patient Response to Anti–PD-L1 Immune Checkpoint Therapy . Journal of the National Cancer Institute .2022

4. 2022 Evaluating the pharmacotherapy of tirzepatide in patients with type 2 diabetes: The consideration of systemic metabolism . Br J Clin Pharmacol .2022

5. 2021 Yung-Fu Wu,Chih-Yang Wang,Wan-Chun Tang,Yu-Cheng Lee,Hoang Dang Khoa Ta,Li-Chia Lin , Syu-Ruei Pan , Yi-Chun Ni , Gangga Anuraga , Kuen-Haur Lee. Expression Profile and Prognostic Value of Wnt Signaling Pathway Molecules in Colorectal Cancer . Biomedicines .2021 ;(9)

6. 2021 Han-Lin Hsu,Hong-Kai Chen,Chi-Hao Tsai,Po-Lin Liao,Yen-Ju Chan,Yu-Cheng Lee , Chen-Chen Lee , Ching-Hao Li. Aryl Hydrocarbon Receptor Defect Attenuates Mitogen-Activated Signaling through Leucine-Rich Repeats and Immunoglobulin-like Domains 1 (LRIG1)-Dependent EGFR Degradation . Int J Mol Sci. .2021 ;(22):9988

7. 2021 Wei-Lun Tsai,Chih-YangWang,Yu-Cheng Lee,Wan-Chun Tang,Gangga Anuraga,Hoang Dang Khoa Ta ,Yung-Fu Wu , Kuen-Haur Lee. A New Light on Potential Therapeutic Targets for Colorectal Cancer Treatment . biomedicines .2021 ;(9):1438

8. 2021 Shiuh-Rong Ho,Yu-Cheng Lee,Michael M Ittmann,Fang-Tsyr Lin,Keith Syson Chan,Weei-Chin Lin. RNF144A deficiency promotes PD-L1 protein stabilization and carcinogen-induced bladder tumorigenesis . Cancer Letter .2021

9. 2021 Cheng-Wei Chou,Yu-Hsiu Hsieh,Su-Chi Ku,Wan-Jou Shen,Gangga Anuraga,Hoang Dang Khoa Ta , Kuen-Haur Lee , Yu-Cheng Lee, Cheng-Hsien Lin , Chih-Yang Wang , Wei-Jan Wang. Potential Prognostic Biomarkers of OSBPL Family Genes in Patients with Pancreatic Ductal Adenocarcinoma . Biomedicines .2021 ;(9):1601

10. 2020 K. Hayashi,F. Nikolos,Y. C. Lee,A. Jain,E. Tsouko, H. Gao, A. Kasabyan, H. E. Leung, A. Osipov, S. Y. Jung, A. V. Kurtova & K. S. Chan. Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death . Nature Communications .2020

11. 2019 Lee YC,Kurtova AV,Xiao J,Nikolos F,Hayashi K,Tramel Z, Jain A, Chen F, Chokshi M, Lee C, Bao G, Zhang X, Shen J, Mo Q, Jung SY, Rowley D, Chan KS. Collagen-rich airway smooth muscle cells are a metastatic niche for tumor colonization in the lung . Nat Commun. .2019

12. 2018 Mo QX,Nikolos F,Chen FG,Tramel Z,Lee YC,Hayashi K, Xiao J, Jianjun Shen, and Chan KS. Prognostic power of a tumor differentiation gene signature for bladder urothelial carcinoma - a comparative analysis and systematic review . Journal of the National Cancer Institute .2018

13. 2017 Rodriguez-Brenes IA,Kurtova AV,Lin C,Lee YC,Xiao J,Mims M, Chan KS, Wodarz D. Cellular Hierarchy as a Determinant of Tumor Sensitivity to Chemotherapy . Cancer Res .2017

14. 2016 Brooks M,Mo Q,Krasnow R,Ho PL,Lee YC,Xiao J, Kurtova A, Lerner S, Godoy G, Jian W, Castro P, Chen F, Rowley D, Ittmann M, Chan KS. Positive association of collagen type I with non-muscle invasive bladder cancer progression . Oncotarget .2016

15. 2015 Lin CH,Li HY,Lee YC,Calkins MJ,Lee KH,Yang CN, Lu PJ. Landscape of Pin1 in the cell cycle . Exp Biol Med .2015

16. 2014 Lin FC,Lee YC,Goan YG,Tsai CH,Yao YC,Cheng HC, Lai WW, Wang YC, Sheu BS, Lu PJ. Pin1 positively affects tumorigenesis of esophageal squamous cell carcinoma and correlates with poor survival of patients . J Biomed Sci .2014

17. 2014 Lee KH,Lin FC,Hsu TI,Lin JT,Guo JH,Tsai CH, Lee YC, Lee YC, Chen CL, Hsiao M, Lu PJ. MicroRNA-296-5p (miR-296-5p) functions as a tumor suppressor in prostate cancer by directly targeting Pin1 . Biochimica et Biophysica Acta - Molecular Cell Research .2014

18. 2013 Liu YP,Yang CJ,Huang MS,Yeh CT,Wu AT,Lee YC, Lai TC, Lee CH, Hsiao YW, Lu J, Shen CN, Lu PJ, Hsiao M. Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling . Cancer Res .2013

19. 2013 Liu YP,Chen HL,Tzeng CC,Lu PJ,Lo CW,Lee YC, Tseng CH, Chen YL, Yang CN. TCH-1030 targeting on topoisomerase I induces S-phase arrest, DNA fragmentation, and cell death of breast cancer cells . Breast Cancer Res Treat .2013

20. 2013 Liu YP,Liao WC,Ger LP,Chen JC,Hsu TI,Lee YC, Chang HT, Chen YC, Jan YH, Lee KH, Zeng YH, Hsiao M, Lu PJ. Carboxyl-Terminal Modulator Protein Positively Regulates Akt Phosphorylation and Acts as an Oncogenic Driver in Breast Cancer . Cancer Res .2013

21. 2013 Wang HY,Fu JC,Lee YC,Lu PJ. Hyperthermia stress activates heat shock protein expression via propyl isomerase 1 regulation with heat shock factor 1 . Mol Cell Biol .2013

22. 2013 Lee YC,Liao PC,Liou YC,Hsiao M,Huang CY,Lu PJ. Glycogen synthase kinase 3β activity is required for hBora/Aurora A-mediated mitotic entry . Cell Cycle .2013

23. 2013 Lee YC,Que J,Chen YC,Lin JT,Liou YC,Liao PC, Liu YP, Lee KH, Lin LC, Hsiao M, Hung LY, Huang CY, Lu PJ. Pin1 acts as a negative regulator of the G2/M transition through an interplay with the Aurora A/hBora complex . Journal of Cell Science .2013

24. 2012 Lin FC,Liu YP,Lai CH,Shan YS,Cheng HC,Hsu PI, Lee CH, Lee YC, Wang HY, Wang CH, Cheng JQ, Hsiao M, Lu PJ. RUNX3-mediated transcriptional inhibition of Akt suppresses tumorigenesis of human gastric cancer cells . Oncogene .2012

25. 2010 Lee CH,Wei YW,Huang YT,Lin YT,Lee YC,Lee KH, Lu PJ. CDK5 phosphorylates eNOS at Ser-113 and regulates NO production . J Cell Biochem .2010

研究計畫

計畫名稱
113 探討膜聯蛋白在膠原蛋白微環境中影響膀胱腫瘤對抗癌藥物敏感性的角色及其臨床治療應用潛力(1/3)
補助單位
國家科學及技術委員會

計畫名稱
112 探討膀胱癌對第三代EGFR標靶藥物 AZD9291治療下產生抗藥性的可能機制
補助單位
國家科學及技術委員會

計畫名稱
112 探討DDR1透過調控IL-1RA表現影響膀胱 癌進展的可能性
補助單位
國家科學及技術委員會

計畫名稱
112 腫瘤微環境應答性之奈⽶複合材料之開發與癌症治療
補助單位
臺北醫學大學

計畫名稱
111 研究細胞外基質膠原蛋白誘發的酸性微環境促進惡性膀胱腫瘤之角色功能探討(2/2)
補助單位
國家科學及技術委員會

計畫名稱
110 探討E3泛素化連接酶(WWP2)對於調控盤狀結構域接受器(DDR1)的蛋白穩定性進而影響細胞增殖、遷移能力之可能性
補助單位
國家科學及技術委員會

計畫名稱
110 研究以糖解作用酵素Enolase-1作為標的,抑制膀胱癌細胞轉移及其調控機制的探討
補助單位
國家科學及技術委員會

計畫名稱
110 研究細胞外基質膠原蛋白誘發的酸性微環境促進惡性膀胱腫瘤之角色功能探討(1/2)
補助單位
科技部

計畫名稱
109 探討DDR1透過Galectin-3促進膀胱癌增殖與遷移之可能性
補助單位
科技部

計畫名稱
109 探討原位及遠端轉移腫瘤微環境藉由酪氨酸激酶接受器DDR1影響膀胱癌的治療策略(2/2)
補助單位
科技部

計畫名稱
108 新聘教師研究補助
補助單位
臺北醫學大學

計畫名稱
108 探討原位及遠端轉移腫瘤微環境藉由酪氨酸激酶接受器DDR1影響膀胱癌的治療策略(1/2)
補助單位
科技部